Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Total Current Liabilities

All obligations due within one year.

Sera Prognostics, Inc.NASDAQ: SERA

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities broadly unchanged from a year ago

Total current liabilities stood at $23.42M at the end of Q1 FY2026, up 0.1% from a year earlier and down 3.2% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.

Context

  • Total current liabilities amounted to 25.0% of total assets at the end of Q1 FY2026, up 5.2 pp from a year earlier.
  • Total current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total current liabilities keeps rising in the next quarterly balance sheet after a +0.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.42M-3.2% QoQ
Last fiscal yearDec 2025
$24.19M-2.3% YoY
Year agoMar 2025
$23.4M+0.1% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.1%——
1 year-2.3%——
3-year CAGR+15.9%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
24.19M USD
Year-over-year change
-2.3%
4-year CAGR
+30.2%

Total Current Liabilities vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +0.1% is the 3rd highest of 9, against a peer median of -7.8%.
  • Total current liabilities amounts to 25.0% of total assets for SERA, versus a peer median of 18.6%.
SERA Competitors
Total Current Liabilities for SERA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LUCDLucid Diagnostics Inc.Mar 2026$29.39M USD-19.6%+50.3%86.2%
SERASera Prognostics, Inc.Mar 2026$23.42M USD+0.1%+15.9%25.0%
RPIDRapid Micro Biosystems, Inc.Mar 2026$19.12M USD+27.5%-1.0%30.7%
SRZNSurrozen, Inc.Mar 2026$9.57M USD-9.6%+0.7%7.9%
APYXApyx Medical CorporationMar 2026$9.45M USD-0.7%-0.4%15.0%
HURATuHURA Biosciences, Inc.Mar 2026$6.07M USD+26.9%+27.3%20.4%
CGTXCognition Therapeutics, Inc.Mar 2026$6.05M USD-44.7%+21.3%16.7%
ONCYOncolytics Biotech Inc.Mar 2026CA$5.42M CAD-6.0%+28.5%66.5%
STSSSkyAI, Inc.Mar 2026$2.22M USD-74.3%+32.8%1.2%
Peer median (excluding SERA) —-7.8%+24.3%18.6%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents58.93M29.88M3.88M4.04M3.94M
Short-term Investments46.18M52.83M45.2M42.19M35.26M
Net Receivables3.14M6.11M11.47M34K12K
Inventory00000
Other Current Assets1.99M1.31M795K19K1.56M
Total Current Assets110.25M90.13M61.34M47.6M40.77M
Property, Plant & Equipment (Net)1.77M3.06M3.18M1.85M3.55M
Goodwill00000
Intangible Assets0001.03M910K
Long-term Investments34.85M21.33M30.84M21.97M56.58M
Tax Assets00000
Other Non-current Assets157K1.82M77K124K123K
Total Non-current Assets36.78M26.2M34.1M24.98M61.16M
Total Assets147.03M116.33M95.44M72.58M101.93M
Account Payables1.2M1.55M1.05M1.97M862K
Short-term Debt00000
Tax Payables00000
Deferred Revenue3.12M9.08M20.24M20.22M20.32M
Other Current Liabilities3.56M1.07M926K20.52M3.01M
Total Current Liabilities8.41M15.54M24.44M24.77M24.19M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities54K1.85M840K2K2.34M
Total Liabilities8.47M17.39M25.28M24.77M26.53M
Common Stock3K3K3K3K4K
Retained Earnings(166.47M)(210.65M)(246.9M)(279.79M)(311.72M)
Accumulated OCI(183K)(981K)(15K)60K262K
Other Stockholders Equity000(0)0
Minority Interest00000
Total Equity138.56M98.94M70.16M47.8M75.41M
Total Debt128K2.83M1.86M840K2.34M
Net Debt(58.8M)(27.05M)(2.02M)(3.2M)(1.61M)

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.